FindTrial
Sign In

Apalutamide placebo

DRUG4 trials

Sponsors

Janssen - Cilag International, Janssen Cilag International, Aragon Pharmaceuticals Inc., Aragon Pharmaceuticals, Inc.

Conditions

Castration-Resistant Prostate CancerHigh- or very-high riskMetastatic Hormone-sensitive Prostate CancerProstatic Neoplasmslocalized or locally advanced prostate cancer

Phase 3

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Active, not recruitingNCT02531516
Aragon Pharmaceuticals, Inc.Prostatic Neoplasms
Start: 2015-11-19End: 2028-12-29Updated: 2026-03-19
Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy
Active, not recruitingCTIS2023-505246-26-00
Janssen - Cilag InternationalHigh- or very-high risk, localized or locally advanced prostate cancer
Start: 2016-01-27Target: 635Updated: 2025-12-16
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Active, not recruitingCTIS2023-509221-47-00
Aragon Pharmaceuticals Inc.Castration-Resistant Prostate Cancer
Start: 2014-02-12Target: 30Updated: 2025-12-09
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormonesensitive Prostate Cancer (mHSPC)
Active, not recruitingCTIS2023-508607-20-00
Janssen Cilag InternationalMetastatic Hormone-sensitive Prostate Cancer
Start: 2015-11-27Target: 7Updated: 2025-08-12

Related Papers

Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC).
Journal of Clinical Oncology2022-06-019 citations
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
BMC Cancer2018-04-0219 citations
Phase-III-Studie beim lokalen oder lokal fortgeschrittenen Prostatakarzinom: Randomisierte, doppelblinde, Placebo-kontrollierte Phase 3 Studie zu Apalutamide in Patienten mit lokalem Hoch-Risiko-Prostatakarzinom oder lokal fortgeschrittenem Prostatakarzinom, die eine primäre Radiotherapie erhalten (ATLAS) – Studie AP 90/15 der AUO
Aktuelle Urologie2017-12-01
ATLAS: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy.
Journal of Clinical Oncology2016-05-2023 citations